Details of the Drug

General Information of Drug (ID: DM28D05)

Drug Name

Oritavancin

Synonyms

Nuvocid; Oritavancin [INN]; LY333328; Chlorobiphenyl-chloroeremomycin; (3S,6R,7R,22R,23S,26S,36R,38aR)-22-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-mannopyranosyloxy)-3-(carbamoylmethyl)-10,19-dichloro-44-[2-O-[3-(4'-chlorobiphenyl-4-ylmethylamino)-2,3,6-trideoxy-3-C-me; (4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabino-hexopyranosyl)-N3''-(4'-chloro[1,1'-biphenyl]-4-ylmethyl)vancomycin; (4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-alpha-L-arabinohexopyranosyl)-N3''-(p-(p-chlorophenyl)benzyl)vancomycin

Indication

Disease Entry	ICD 11	Status	REF
Bacterial infection	1A00-1C4Z	Approved	[1]
Gram-positive bacterial infection	1B74-1G40	Terminated	[2]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL is unavailable

2D MOL

#Ro5 Violations (Lipinski): 4

Molecular Weight (mw)

1793.1

Logarithm of the Partition Coefficient (xlogp)

1.5

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 2800 mgh/L [3]
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 138 mg/L [3]
Clearance: The renal clearance of drug is 0.457 mL/min [3]
Elimination: Less than 5% of drug is recovered in the urine, and 1% of drug is recovered in the feces [4]
Half-life: The concentration or amount of drug in body reduced by one-half in 245 hours [3]
Metabolism: The drug is not metabolised [5]
Unbound Fraction: The unbound fraction of drug in plasma is 0.13% [6]
Vd: The volume of distribution (Vd) of drug is 87.6 L [3]

Chemical Identifiers

Formula: C86H97Cl3N10O26
IUPAC Name: (1S,2R,18R,19R,22S,25R,28R,40S)-2-[(2R,4S,5R,6S)-4-amino-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-22-(2-amino-2-oxoethyl)-5,15-dichloro-48-[(2S,3R,4S,5S,6R)-3-[(2S,4S,5R,6S)-4-[[4-(4-chlorophenyl)phenyl]methylamino]-5-hydroxy-4,6-dimethyloxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-18,32,35,37-tetrahydroxy-19-[[(2R)-4-methyl-2-(methylamino)pentanoyl]amino]-20,23,26,42,44-pentaoxo-7,13-dioxa-21,24,27,41,43-pentazaoctacyclo[26.14.2.23,6.214,17.18,12.129,33.010,25.034,39]pentaconta-3,5,8,10,12(48),14,16,29(45),30,32,34(39),35,37,46,49-pentadecaene-40-carboxylic acid
Canonical SMILES: C[C@H]1[C@@H]([C@@](C[C@@H](O1)O[C@H]2[C@H]3C(=O)N[C@@H](C4=C(C(=CC(=C4)O)O)C5=C(C=CC(=C5)[C@H](C(=O)N3)NC(=O)[C@H]6C7=CC(=C(C(=C7)OC8=C(C=C2C=C8)Cl)O[C@H]9[C@@H]([C@H]([C@@H]([C@H](O9)CO)O)O)O[C@H]1C[C@]([C@H]([C@@H](O1)C)O)(C)NCC1=CC=C(C=C1)C1=CC=C(C=C1)Cl)OC1=C(C=C(C=C1)[C@H]([C@H](C(=O)N[C@H](C(=O)N6)CC(=O)N)NC(=O)[C@@H](CC(C)C)NC)O)Cl)O)C(=O)O)(C)N)O
InChI: InChI=1S/C86H97Cl3N10O26/c1-35(2)22-51(92-7)77(110)98-67-69(105)42-15-20-55(49(88)24-42)120-57-26-44-27-58(73(57)125-84-74(71(107)70(106)59(34-100)122-84)124-62-32-86(6,76(109)37(4)119-62)93-33-38-8-10-39(11-9-38)40-12-17-45(87)18-13-40)121-56-21-16-43(25-50(56)89)72(123-61-31-85(5,91)75(108)36(3)118-61)68-82(115)97-66(83(116)117)48-28-46(101)29-54(103)63(48)47-23-41(14-19-53(47)102)64(79(112)99-68)96-80(113)65(44)95-78(111)52(30-60(90)104)94-81(67)114/h8-21,23-29,35-37,51-52,59,61-62,64-72,74-76,84,92-93,100-103,105-109H,22,30-34,91H2,1-7H3,(H2,90,104)(H,94,114)(H,95,111)(H,96,113)(H,97,115)(H,98,110)(H,99,112)(H,116,117)/t36-,37-,51+,52-,59+,61-,62-,64+,65+,66-,67+,68-,69+,70+,71-,72+,74+,75-,76-,84-,85-,86-/m0/s1
InChIKey: VHFGEBVPHAGQPI-LXKZPTCJSA-N

Cross-matching ID

PubChem CID: 16136912
ChEBI ID: CHEBI:82699
CAS Number: 171099-57-3
DrugBank ID: DB04911
TTD ID: D02IBU

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Bacterial Dihydropteroate synthetase (Bact folP)	TT4ILYC	DHPS_ECOLI	Inhibitor	[7]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Oritavancin (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Midostaurin	DMI6E0R	Moderate	Increased metabolism of Oritavancin caused by Midostaurin mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[8]
Gilteritinib	DMTI0ZO	Moderate	Increased metabolism of Oritavancin caused by Gilteritinib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[9]
Oliceridine	DM6MDCF	Moderate	Increased metabolism of Oritavancin caused by Oliceridine mediated induction of CYP450 enzyme.	Acute pain [MG31]	[10]
LY2835219	DM93VBZ	Moderate	Increased metabolism of Oritavancin caused by LY2835219 mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[11]
Tucatinib	DMBESUA	Moderate	Increased metabolism of Oritavancin caused by Tucatinib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[12]
Alpelisib	DMEXMYK	Moderate	Increased metabolism of Oritavancin caused by Alpelisib mediated induction of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[13]
Osilodrostat	DMIJC9X	Moderate	Increased metabolism of Oritavancin caused by Osilodrostat mediated induction of CYP450 enzyme.	Cushing syndrome [5A70]	[14]
Bay 80-6946	DMLOS5R	Moderate	Increased metabolism of Oritavancin caused by Bay 80-6946 mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[15]
Tazemetostat	DMWP1BH	Moderate	Increased metabolism of Oritavancin caused by Tazemetostat mediated induction of CYP450 enzyme.	Follicular lymphoma [2A80]	[16]
Ripretinib	DM958QB	Moderate	Increased metabolism of Oritavancin caused by Ripretinib mediated induction of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[17]
Avapritinib	DMK2GZX	Moderate	Increased metabolism of Oritavancin caused by Avapritinib mediated induction of CYP450 enzyme.	Gastrointestinal stromal tumour [2B5B]	[18]
MK-1439	DM215WE	Moderate	Increased metabolism of Oritavancin caused by MK-1439 mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[19]
Fostemsavir	DM50ILT	Minor	Increased metabolism of Oritavancin caused by Fostemsavir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[20]
Cobicistat	DM6L4H2	Moderate	Increased metabolism of Oritavancin caused by Cobicistat mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[21]
Elvitegravir	DMG9B1U	Moderate	Increased metabolism of Oritavancin caused by Elvitegravir mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[17]
Rilpivirine	DMJ0QOW	Moderate	Increased metabolism of Oritavancin caused by Rilpivirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[17]
ITI-007	DMUQ1DO	Major	Increased metabolism of Oritavancin caused by ITI-007 mediated induction of CYP450 enzyme.	Insomnia [7A00-7A0Z]	[22]
Pemigatinib	DM819JF	Moderate	Increased metabolism of Oritavancin caused by Pemigatinib mediated induction of CYP450 enzyme.	Liver cancer [2C12]	[18]
Crizotinib	DM4F29C	Moderate	Increased metabolism of Oritavancin caused by Crizotinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[23]
Brigatinib	DM7W94S	Moderate	Increased metabolism of Oritavancin caused by Brigatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[17]
Lurbinectedin	DMEFRTZ	Moderate	Increased metabolism of Oritavancin caused by Lurbinectedin mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[24]
Capmatinib	DMYCXKL	Moderate	Increased metabolism of Oritavancin caused by Capmatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[25]
Selpercatinib	DMZR15V	Moderate	Increased metabolism of Oritavancin caused by Selpercatinib mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[18]
Acalabrutinib	DM7GCVW	Moderate	Increased metabolism of Oritavancin caused by Acalabrutinib mediated induction of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[26]
Vemurafenib	DM62UG5	Moderate	Increased metabolism of Oritavancin caused by Vemurafenib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[27]
Selumetinib	DMC7W6R	Moderate	Increased metabolism of Oritavancin caused by Selumetinib mediated induction of CYP450 enzyme.	Melanoma [2C30]	[28]
LGX818	DMNQXV8	Moderate	Increased metabolism of Oritavancin caused by LGX818 mediated induction of CYP450 enzyme.	Melanoma [2C30]	[29]
Ubrogepant	DM749I3	Moderate	Increased metabolism of Oritavancin caused by Ubrogepant mediated induction of CYP450 enzyme.	Migraine [8A80]	[30]
Entrectinib	DMMPTLH	Moderate	Increased metabolism of Oritavancin caused by Entrectinib mediated induction of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[31]
Pimavanserin	DMR7IVC	Moderate	Increased metabolism of Oritavancin caused by Pimavanserin mediated induction of CYP450 enzyme.	Parkinsonism [8A00]	[32]
Macimorelin	DMQYJIR	Moderate	Increased metabolism of Oritavancin caused by Macimorelin mediated induction of CYP450 enzyme.	Pituitary gland disorder [5A60-5A61]	[33]
Lefamulin	DME6G97	Moderate	Increased metabolism of Oritavancin caused by Lefamulin mediated induction of CYP450 enzyme.	Pneumonia [CA40]	[34]
Lonafarnib	DMGM2Z6	Moderate	Increased metabolism of Oritavancin caused by Lonafarnib mediated induction of CYP450 enzyme.	Premature ageing appearance [LD2B]	[35]
Darolutamide	DMV7YFT	Moderate	Increased metabolism of Oritavancin caused by Darolutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[36]
Silodosin	DMJSBT6	Moderate	Increased metabolism of Oritavancin caused by Silodosin mediated induction of CYP450 enzyme.	Prostate hyperplasia [GA90]	[17]
Temsirolimus	DMS104F	Moderate	Increased metabolism of Oritavancin caused by Temsirolimus mediated induction of CYP450 enzyme.	Renal cell carcinoma [2C90]	[17]
Larotrectinib	DM26CQR	Moderate	Increased metabolism of Oritavancin caused by Larotrectinib mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[17]
LEE011	DMMX75K	Moderate	Increased metabolism of Oritavancin caused by LEE011 mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[17]
Brilinta	DMBR01X	Moderate	Increased metabolism of Oritavancin caused by Brilinta mediated induction of CYP450 enzyme.	Thrombosis [DB61-GB90]	[21]
Cabozantinib	DMIYDT4	Moderate	Increased metabolism of Oritavancin caused by Cabozantinib mediated induction of CYP450 enzyme.	Thyroid cancer [2D10]	[37]
Elagolix	DMB2C0E	Moderate	Increased metabolism of Oritavancin caused by Elagolix mediated induction of CYP450 enzyme.	Uterine fibroid [2E86]	[38]
-----------


⏷ Show the Full List of 41 DDI Information of This Drug

References

1	2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
2	How many modes of action should an antibiotic have Curr Opin Pharmacol. 2008 Oct;8(5):564-73.
3	FDA Approved Drug Products: Orbactiv (oritavancin) for intravenous injection
4	Bhavnani SM, Owen JS, Loutit JS, Porter SB, Ambrose PG: Pharmacokinetics, safety, and tolerability of ascending single intravenous doses of oritavancin administered to healthy human subjects. Diagn Microbiol Infect Dis. 2004 Oct;50(2):95-102.
5	Kaempf-Rotzoll DE, Traber MG, Arai H: Vitamin E and transfer proteins. Curr Opin Lipidol. 2003 Jun;14(3):249-54. doi: 10.1097/01.mol.0000073505.41685.09.
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Emerging drugs for bacterial urinary tract infections. Expert Opin Emerg Drugs. 2005 May;10(2):275-98.
8	Dutreix C, Munarini F, Lorenzo S, Roesel J, Wang Y "Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers." Cancer Chemother Pharmacol 72 (2013): 1223-34. [PMID: 24085261]
9	Product Information. Xospata (gilteritinib). Astellas Pharma US, Inc, Deerfield, IL.
10	Altice FL, Friedland GH, Cooney EL "Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone." AIDS 13 (1999): 957-62. [PMID: 10371177]
11	Product Information. Verzenio (abemaciclib). Lilly, Eli and Company, Indianapolis, IN.
12	Product Information. Tukysa (tucatinib). Seattle Genetics Inc, Bothell, WA.
13	Product Information. Piqray (alpelisib). Novartis Pharmaceuticals, East Hanover, NJ.
14	Product Information. Isturisa (osilodrostat). Recordati Rare Diseases Inc, Lebanon, NJ.
15	Product Information. Aliqopa (copanlisib). Bayer Pharmaceutical Inc, West Haven, CT.
16	Product Information. Tazverik (tazemetostat). Epizyme, Inc, Cambridge, MA.
17	Cerner Multum, Inc. "Australian Product Information.".
18	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
19	Product Information. Pifeltro (doravirine). Merck & Company Inc, Whitehouse Station, NJ.
20	Product Information. Rukobia (fostemsavir). ViiV Healthcare, Research Triangle Park, NC.
21	Canadian Pharmacists Association.
22	Product Information. Caplyta (lumateperone). Intra-Cellular Therapies, Inc., New York, NY.
23	Cerner Multum, Inc. "Canadian Product Information.".
24	Product Information. Zepzelca (lurbinectedin). Jazz Pharmaceuticals, Palo Alto, CA.
25	Product Information. Tabrecta (capmatinib). Novartis Pharmaceuticals, East Hanover, NJ.
26	Product Information. Calquence (acalabrutinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
27	Product Information. Zelboraf (vemurafenib). Genentech, South San Francisco, CA.
28	Product Information. Koselugo (selumetinib). Astra-Zeneca Pharmaceuticals, Wilmington, DE.
29	Product Information. Braftovi (encorafenib). Array BioPharma Inc., Boulder, CO.
30	Product Information. Ubrelvy (ubrogepant). Allergan Inc, Irvine, CA.
31	Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
32	Product Information. Nuplazid (pimavanserin). Accelis Pharma, East Windsor, NJ.
33	Product Information. Macrilen (macimorelin). Aeterna Zentaris, Charleston, SC.
34	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
35	Product Information. Zokinvy (lonafarnib). Eiger BioPharmaceuticals, Palo Alto, CA.
36	Product Information. Nubeqa (darolutamide). Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ.
37	Product Information. Cabometyx (cabozantinib). Exelixis Inc, S San Francisco, CA.
38	Product Information. Orilissa (elagolix). AbbVie US LLC, North Chicago, IL.